Muutke küpsiste eelistusi

E-raamat: Charnolophagy in Health and Disease: With Special Reference to Nanotheranostics [Taylor & Francis e-raamat]

(American International school of Medicine, Guyana)
  • Formaat: 608 pages, 15 Tables, black and white; 8 Illustrations, color; 42 Illustrations, black and white
  • Ilmumisaeg: 03-Sep-2021
  • Kirjastus: CRC Press
  • ISBN-13: 9780367809096
  • Taylor & Francis e-raamat
  • Hind: 290,82 €*
  • * hind, mis tagab piiramatu üheaegsete kasutajate arvuga ligipääsu piiramatuks ajaks
  • Tavahind: 415,45 €
  • Säästad 30%
  • Formaat: 608 pages, 15 Tables, black and white; 8 Illustrations, color; 42 Illustrations, black and white
  • Ilmumisaeg: 03-Sep-2021
  • Kirjastus: CRC Press
  • ISBN-13: 9780367809096

This book introduces charnolophagy (CP) as energy-driven, lysosomal-dependent mitochondrial inclusion-specific pleomorphic Charnoly body (CB) autophagy (ATG) involving free radical-induced Ca2+ dyshomeostasis, ?? collapse, and ATP depletion in congenital diseases, pressure ulcers, metabolic diseases, hepatic diseases, diabetes, obesity, inflammatory diseases, musculoskeletal diseases, sarcopenia, cachexia, respiratory diseases, gastrointestinal diseases, hyperlipidemia, skin and hair diseases, pulmonary diseases, cardiovascular diseases, renal diseases, sepsis-induced multi-organ failure, reproductive diseases, inflammatory diseases, ophthalmic diseases, neurodegenerative diseases, drug addiction, aging, microbial (including COVID-19) infections, and belligerent malignancies implicated in early morbidity and mortality and disease-specific spatiotemporal, targeted, safe, and effective evidence-based personalized theranostic charnolopharmacotherapeutics to cure them. Basic DRESS and GELS principles, nanoparticles to cure chronic multidrug-resistant (MDR) diseases, antioxidants as free radical scavengers, CB antagonists, CP regulators, and CS stabilizers to curb CB molecular pathogenesis (CBMP) are described for better quality of life and longevity. Specific guidelines for environmental protection and preservation of zoological and botanical species at the verge of extinction, Triple "I" Hypothesis for mitochondrial quality control, and transcriptional regulation of CSexR and CSendoR to cure chronic diseases are presented. Novel CP index is introduced to evaluate MDR malignancies and other chronic diseases. WHO, CDC, FDA, NIH, policy planners, cosmetologists, trichologists, players, athletes, dancers, wrestlers, equestrians, young women, aging population, toxicologists, environmental protectionists, pharmaceutical industry, biomedical scientists, researchers, medical students, physicians, nurses, paramedical professionals, and global audience will be interested in this interesting book to prevent pandemics and raise healthcare awareness.

Preface iii
Acknowledgements vii
Abbreviations ix
Definitions xvii
Introduction 1(77)
Concluding Remarks 78(5)
Part-1 Charnolophagy (General Topics)
Chapter-1 Charnolophagy as Immediate and Early ATG
83(4)
Chapter-2 Charnolophagy in Intramitochondrial and Intracellular Detoxification
87(15)
Chapter-3 Charnolophagy as a Biomarker of Novel Drug Discovery
102(4)
Chapter-4 Organ and Disease-specific Charnolophagy
106(10)
Chapter-5 Charnolophagy in Pressure Ulcers
116(12)
Chapter-6 Charnolophagy in Toxicology
128(11)
Part-2 Charnolophagy in Metabolic Disorders
Chapter-7 Charnolophagy in Congenital Diseases
139(18)
Chapter-8 Charnolophagy in Inborn Errors of Metabolism (Recent Update)
157(23)
Chapter-9 Charnolophagy in Malnutrition
180(16)
Chapter-10 Charnolophagy in Diet Restriction
196(6)
Chapter-11 Charnolophagy in Gastrointestinal Diseases
202(7)
Chapter-12 Charnolophagy in Liver Diseases
209(22)
Chapter-13 Charnolophagy in Diabetes
231(11)
Chapter-14 Charnolophagy in Obesity
242(7)
Chapter-15 Charnolophagy in Hyperlipidemia
249(8)
Part-3 Charnolophagy in Systemic Disorders
Chapter-16 Charnolophagy in Skin and Hair Diseases
257(11)
Chapter-17 Charnolophagy in Musculoskeletal Diseases
268(18)
Chapter-18 Charnolophagy in Pulmonary Diseases
286(12)
Chapter-19 Charnolophagy in Cardiovascular Diseases
298(22)
Chapter-20 Charnolophagy in Renal Diseases
320(5)
Chapter-21 Charnolophagy in Reproductive Diseases
325(13)
Chapter-22 Charnolophagy in Ophthalmic Diseases
338(9)
Chapter-23 Charnolophagy in Neurodegenerative Diseases (Part 1)
347(9)
Chapter-24 Charnolophagy in Neurodegenerative Diseases (Part 2)
356(10)
Chapter-25 Charnolophagy in Parkinson's Disease
366(19)
Chapter-26 Charnolophagy in Alzheimer's Disease
385(7)
Chapter-27 Charnolophagy in Stroke
392(9)
Part-4 Charnolophagy in Inflammation, Cancer, Microbial Infections, and Aging
Chapter-28 Charnolophagy in Inflammatory Diseases
401(16)
Chapter-29 Charnolophagy in Cancer (A)
417(24)
Chapter-30 Charnolophagy in Cancer (B)
441(27)
Chapter-31 Charnolophagy in Microbial Infections
468(35)
Chapter-32 Charnolophagy in Aging
503(24)
Part-5 Charnolophagy in Nanomedicine
Chapter-33 Charnolophagy in Nanotheranostics (Part 1)
527(40)
Chapter-34 Charnolophagy in Nanotheranostics (Part 2)
567(14)
Index 581
Sushil Sharma is Academic Dean, AISM, Georgetown, Guyana (Stone Mountain, Atlanta, USA). Prof. & Course Director, SJSM, Bonaire and St Vincent (2011-2017). Received Ph.D. (AIIMS, Delhi, India); Radiopharmaceutical Training (BARC, Bombay), GE, Siemens, Agilent Technologies, Cardinal Health (U.S. A), Royal Society Fellowship (U.K:1988-89); MHRC Post-Doctoral Fellowship (Canada: 1989-91), 5 Gold Medals. Research Officer (AIIMS:1979-88); Research Officer (University of Montreal:1993-94); Research Associate (McGill University:1994-95); Senior Scientific Officer (IRCM, Montreal:1995-97); Scientist-E (DRDO, Delhi:1997); Scientist (U of M, Winnipeg:1997-99); Assist. Prof.2000-04; Assoc. Prof. Director, UND School of Medicine, Grand Forks:2004-08); Assoc. Prof. Director (Methodist Hospital), Scientist (TMC, Houston: 2008-11), Conference Organizer, Discovered Charnoly Body.